oncology_research

Cambridge, Mass. – September 13, 2026 -- Marengo Therapeutics has completed enrollment in the monotherapy cohorts of its Phase 1/2 STARt-001 trial evaluating invikafusp alfa across eight distinct PD-1-resistant tumor types, with updated results selected for an oral presentation at the ESMO 2026 Congress in Madrid, October 23-27.

Trial enrollment closes across eight PD-1-resistant tumor types

The monotherapy cohorts covered patients with MSS colorectal cancer, PD-L1-negative non-small cell lung cancer and triple-negative breast cancer, among others resistant to checkpoint blockade. Enrollment continues in standard-of-care combination cohorts, while the company plans to name lead indications for focused development alongside the ESMO data release.

San Diego – September 09, 2026 -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) will webcast primary endpoint results from the randomized, controlled Phase 2 portion of its HexAgon study on Tuesday, September 8, 2026 at 5:00 a.m. Pacific Time.

Phase 2 data will compare INBRX-106 combination therapy against pembrolizumab alone

The study evaluates INBRX-106, a hexavalent OX40 agonist, combined with pembrolizumab against pembrolizumab monotherapy as a control arm. The trial enrolled first-line, treatment-naïve patients with PD-L1 positive (CPS ≥ 20) metastatic or unresectable recurrent Head and Neck Squamous Cell Carcinoma (HNSCC).

SOUTH SAN FRANCISCO, Calif. -- September 01, 2026 -- IDEAYA Biosciences said its FDA Type C meeting on IDE849, a DLL3-targeting antibody drug conjugate, produced agreement on a Phase 3 registrational trial design for extensive stage small cell lung cancer (ES-SCLC). The Nasdaq-listed company (IDYA) plans to enroll roughly 400 patients who have already received tarlatamab, randomizing them 1:1 between IDE849 monotherapy and an investigator's choice control arm of topotecan and amrubicin. IDEAYA is targeting trial initiation by year-end 2026.